1. WOK announces a sale of approximately 39 million shares at $0.075 each. 2. The offering will raise gross proceeds of about $2.9 million. 3. Completion of the offering is expected by September 26, 2025.
The capital raised can enhance operational capabilities and fund growth initiatives, similar to how past capital raises have positively influenced stock performance.
The share offering is directly relevant since it generates capital for growth, which is crucial for investor confidence. Such moves often attract positive market sentiments and relevance in future earnings expectations.
Immediate effects from the capital infusion may improve WOK's liquidity and investments, evident when similar firms saw stock price rises shortly after announcements.
Hangzhou, China, Sept. 25, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ: WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it has entered into an agreement with several investors for the purchase and sale of 38,999,334 of the Company's Class A ordinary share, par value $0.0005 per share (the "Shares") (or pre-funded warrants in lieu thereof) at a purchase price of $0.075 per share in a registered direct offering (the "Offering"). The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.0005 per share.
The gross proceeds to the Company of the Offering are expected to be approximately $2.9 million. The transaction is expected to close on or about September 26, 2025, subject to the satisfaction of customary closing conditions.
Univest Securities, LLC is acting as the sole placement agent.
The Offering is being made pursuant to a shelf registration statement on Form F-3 (File No. 333-289943) previously filed by the Company and declared effective by the U.S. Securities and Exchange Commission (the "SEC") on September 15, 2025. A final prospectus supplement and accompanying prospectus describing the terms of the proposed Offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Univest Securities, LLC at info@univest.us, or by calling +1 (212) 343-8888.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Copies of the prospectus supplement relating to the registered direct Offering, together with the accompanying base prospectus will be filed by the Company and, upon filing, can be obtained at the SEC's website at www.sec.gov.
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company's website: https://www.workmedtech.com/corporate.
Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company's annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
For more information, please contact:
WORK Medical Technology Group LTD
Investor Relations Department
Email: ir@workmedtech.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
